Osteoporosis
📧 Sign up to get email alerts when something new happens for Osteoporosis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-27EMA Authorised: Kauliv (teriparatide) — Strides Pharma (Cyprus) Limited
Kauliv (teriparatide) has been authorised by the EMA for osteoporosis-related indications, including postmenopausal osteoporosis, by Strides…
-
EMA approval · 2026-08-24EMA Authorised: Izamby (denosumab) — Mabxience Research SL
EMA authorises Izamby (denosumab) for bone resorption disorders including osteoporosis and postmenopausal osteoporosis.
-
EMA approval · 2026-08-20EMA Authorised: Junod (denosumab) — Gedeon Richter Plc.
Authorisation of Junod (denosumab) by Gedeon Richter Plc. for conditions related to bone resorption and osteoporosis, including postmenopaus…
-
EMA approval · 2026-08-19EMA Authorised: Prolia (denosumab) — Amgen Europe B.V.
EMA authorises Prolia (denosumab) for osteoporosis-related indications, confirming market approval in the European Union.
-
EMA approval · 2026-08-18EMA Authorised: Conexxence (denosumab) — Fresenius Kabi Deutschland GmbH
EMA authorised Conexxence (denosumab) for osteoporosis indications, including postmenopausal osteoporosis and bone resorption conditions.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-08-07Clinical Trial Update: A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis [Phase 3]
Phase 3 trial evaluating efficacy, safety, and immunogenicity of 9MW0311 in postmenopausal women with osteoporosis has completed.
-
EMA approval · 2026-08-04EMA Authorised: Obodence (denosumab) — Samsung Bioepis NL B.V.
Obodence (denosumab) has been authorised in the EU for osteoporosis and related bone resorption indications.
-
EMA approval · 2026-07-17EMA Authorised: Kefdensis (denosumab) — Stada Arzneimittel AG
The EMA has authorised Kefdensis (denosumab) by Stada Arzneimittel AG for conditions related to bone resorption and osteoporosis, including …
-
EMA approval · 2026-07-14EMA Authorised: Bildyos (denosumab) — Sciencepharma Sp. z o.o
The EMA has authorised Bildyos (denosumab) by Sciencepharma Sp. z o.o. for bone resorption disorders including osteoporosis, including postm…
-
EMA approval · 2026-07-14EMA Authorised: Acvybra (denosumab) — Reddy Holding GmbH
EMA authorised Acvybra (denosumab) for osteoporosis-related indications in Europe, with Reddy Holding GmbH as MAH.
-
EMA approval · 2026-07-09EMA Authorised: Evenity (romosozumab) — UCB Pharma S.A.
Evenity (romosozumab) has been authorised in the EU for osteoporosis. The marketing authorisation holder is UCB Pharma S.A.
-
EMA approval · 2026-06-16EMA Authorised: Kefdensis (denosumab) — Stada Arzneimittel AG
Authorised status for Kefdensis (denosumab) by Stada Arzneimittel AG for bone resorption disorders including osteoporosis and postmenopausal…
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Results: Abaloparatide Before Total Knee Arthroplasty [Phase 4]
Phase 4 trial evaluating abaloparatide before knee replacement surgery, completed with results posted.
-
EMA approval · 2026-04-24EMA Authorised: Vysribli (previously Denosumab Intas) (denosumab) — Intas Third Party Sales 2005 S.L.
EMA authorised Vysribli (denosumab) for osteoporosis indications, including postmenopausal osteoporosis, with MAH Intas Third Party Sales 20…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Virtual Intervention for Vertebral frActure: a Pilot, Feasibility Study for a Multicentre Randomized Controlled Trial [NA]
A completed pilot feasibility study evaluating a virtual intervention for vertebral fractures in osteoporosis, intended to inform a multicen…
-
EMA approval · 2026-04-23EMA Authorised: Terrosa (teriparatide) — Gedeon Richter Plc.
The EU authorised Terrosa, a teriparatide product by Gedeon Richter, for osteoporosis.
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study [Phase 4]
A Phase 4 pilot study evaluating discontinuation and switching strategies for denosumab in glucocorticoid-induced osteoporosis.
-
EMA approval · 2026-04-22EMA Authorised: Movymia (teriparatide) — STADA Arzneimittel AG
The EMA authorised Movymia, a teriparatide product by STADA Arzneimittel AG, for the treatment of osteoporosis in the EU.
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Clinical Relevance of Modifying RANKL Signaling During Folliculogenesis [NA]
This clinical trial update notes the potential relevance of modifying RANKL signaling during folliculogenesis in women with infertility, wit…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Resistance Exercise Training to Improve Bone and Articular Cartilage Health in Women [NA]
This clinical trial entry describes a study evaluating whether resistance exercise training can improve bone and articular cartilage health …
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Bone Marrow Fat and Bariatric Surgery-Mediated Bone Loss
A clinical trial update describing a study on how bariatric surgery in postmenopausal women influences bone loss and bone marrow fat. The st…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI [Phase 2]
A Phase 2 clinical trial is evaluating romosozumab to improve bone mineral density and bone architecture in adults with chronic spinal cord …
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: Multifaceted Intervention Using Telehealth to Reduce the Risk of Falls and Fractures in Older Men [NA]
A telehealth-based multifaceted intervention was studied to reduce falls and fractures in older men with osteoporosis; the trial has complet…
-
EMA approval · 2026-04-20EMA Authorised: Aclasta (zoledronic acid) — Sandoz Pharmaceuticals d.d.
The EMA authorised Sandoz's Aclasta (zoledronic acid) for osteoporosis indications, including postmenopausal osteoporosis and Paget disease …
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Food Trial Evaluating Fecal Abundance of SBD111 With Once-Daily Versus Twice-Daily Administration in Healthy Adults [NA]
Solarea Bio is testing the probiotic SBD111 in healthy adults to compare once-daily versus twice-daily dosing; the study relates to osteopen…